1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf . Accessed 27 Aug 2014
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf . Accessed 27 Aug 2014
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.
4. U.S. Department of Health and Human Services - Food and Drug Administration - Center for Drug Evaluation and Research. Guidance for industry—bioavailability and bioequivalence studies for orally administered products - general considerations. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070124.pdf . Accessed 27 Aug 2014
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Statistical approaches to establishing bioequivalence. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070244.pdf . Accessed 08 Jun 2014